Biomedical Systems Announces Vice President, Imaging Services
Biomedical Systems, a global provider of centralized diagnostic testing for the pharmaceutical and medical device industry, recently announced the promotion of Sam Dranoff to Vice Present of Business Development, Imaging Services.
Biomedical Systems Announces Vice President, Imaging Services
August 27, 2008 – St. Louis, MO – Biomedical Systems, a global leader in centralized diagnostic testing for the pharmaceutical and medical device industry, recently announced the promotion of Sam Dranoff to Vice Present of Business Development, Imaging Services. Dranoff will continue with his current responsibilities while growing a team of global business development directors for Biomedical Systems, Imaging Services. The business unit has experienced significant growth since Dranoff joined the division in 2005, and most recently served as Managing Director, Commercial Operations.
"We have grown the imaging business to a point where we see a need for expanding the Business Development team. Sam has the proven experience and talent to grow and manage this team as well as the vision to see it succeed. That is why I'm so excited that he has accepted this new position and I'm confident that he will add great value in his new role." said Jesse Bowden, President of Imaging Services, Biomedical Systems.
Biomedical Systems is a fully digital imaging core lab that supports clinical trials in dozens of therapeutic categories. Leveraging combined corporate resources that includes ECG core lab and respiratory core lab, Biomedical Imaging Services provides sponsors unmatched diagnostic service offerings on a global basis.
Biomedical Systems is a global provider of centralized diagnostic services for the pharmaceutical and medical device industries. With offices in North America, Europe and Asia, Biomedical Systems has worked with over 11,000 investigative sites in 75 countries around the world for Phase I - IV clinical trials. Biomedical Systems centralized services include the acquisition, analysis and management of data for Cardiac, Imaging and Respiratory modalities used to determine safety and efficacy for drugs and devices in clinical trials. For more information about Biomedical Systems, please contact Traci Cardenas, Marketing Manager at 1-800-877-6334 (3338) or via email, tcardenas@biomedsys.com. Additional information can be found on the company website at www.biomedsys.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
